1127 Biogen Sage
BioCentury & Getty Images

Deals

With $1.5B Sage deal, Biogen bolsters Phase III pipeline ahead of aducanumab decision

By stephen Hansen, associate editor
Nov 27, 2020 | 5:09 PM GMT
Editor's note: This article has been updated to add comments from Biogen's Nov. 30 conference call to discuss the deal. Updated on Dec 1, 2020 at 1:46 AM GMT

Biogen is paying Sage $1.5 billion up front to gain rights to two late-stage CNS products, bolstering the company’s pipeline as it approaches one of the biggest binary decisions in recent industry memory —

Read the full 585 word article

How to gain access

Continue reading with a
two-week free trial.